glp-1 cardiovascular outcomes 2025 news of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice The Latest topics of Standards

The FDA decision is anticipated in 4Q 2025

Compounded vs brand-name Powerful active ingredient

Dann wirst du Audible lieben

"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA." The Lancet , 2023

I would not recommend microdosing GLP-1s for individuals with significant amounts of weight to lose or known metabolic dysregulation. The bottom line is that there are still questions regarding the effectiveness and safety of microdosing GLP-1 medications, and this type of regimen is not for everyone

As the pharmaceutical options expand and potentially become more accessible, the competitive landscape for natural GLP-1 support products will shift